Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: AMRI | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: AMRI

Achieves record contract revenues

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

AMRI
 
4Q Revenues: $67.1 million (flat)

4Q Earnings: $4.5 million (+137%)

FY Revenues: $246.6 million (+9%)

FY Earnings: $12.7 million (loss of $3.8 million FY12)

Comments: Contract revenue for the quarter was a record $59.7 million, up 1%. Royalty revenue in the quarter was $7.4 million, down 9%, and includes royalties from the Allegra products as well as $2.3 million from sales of certain amphetamine salts sold by Actavis. Contract revenue for the year was a record $210.0 million, up 11%, while royalty revenue was $36.6 million, up 2%. Discovery Services and Development / Small Scale Manufacturing (DDS) contract revenue for the quarter was $18.4 million, down 12%, with lower revenue in Development / Small Scale Manufacturing, partially offset by higher Discovery Services revenue, and for the year was $77.4 million, up 5%. Large Scale Manufacturing revenue for the quarter was $41.3 million, up 8%, and $132.6 million for the year, up 14%.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters